Modified GRF (1-29)

Origin and Structure

Modified GRF (1-29) — often abbreviated Mod GRF, and sometimes referred to as "CJC-1295 without DAC" — is a stabilized analogue of the first 29 amino acids of human growth hormone releasing hormone. The native GHRH(1-29) fragment (sermorelin) is biologically active but plasma-unstable, with a half-life near 12 minutes driven mostly by dipeptidyl peptidase-4 (DPP-4) cleavage at the N-terminus. Mod GRF was designed at ConjuChem in the early 2000s to address that weakness with four specific substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27.

The D-Ala-2 substitution blocks DPP-4 cleavage; Gln-8 prevents asparagine-mediated backbone cleavage; Ala-15 increases amphipathic helix stability; and Leu-27 blocks oxidative degradation. The result is a 30-minute-plus plasma half-life — long enough to produce a clean GH pulse, short enough to preserve pulsatile kinetics rather than producing the sustained elevation that full-length CJC-1295 with DAC creates.

Mechanism of Action

Mod GRF (1-29) is a GHRH receptor agonist with the same mechanism as endogenous GHRH: cAMP-mediated GH synthesis and release from pituitary somatotrophs, preserved negative feedback via somatostatin and IGF-1. The practical contrast with CJC-1295 with DAC (drug affinity complex) is important: DAC-conjugated CJC-1295 has a half-life of roughly 8 days due to albumin binding, which produces a continuous "GH bleed" rather than discrete pulses. Mod GRF preserves pulsatility, which most endocrinology researchers consider the more physiologic pattern and which synergizes more cleanly with GHRPs.

Why Mod GRF Is Almost Always Stacked

Unlike sermorelin or tesamorelin, Mod GRF is rarely used as a monotherapy. Its design purpose is to serve as the GHRH half of a GHRH-plus-GHRP stack. The two mechanisms synergize at the somatotroph level — GHRH drives amplitude, GHRPs drive frequency and reinforce amplitude through a separate signaling cascade — and co-administration produces GH pulses substantially larger than either compound alone. The ipamorelin-plus-Mod GRF combination is the most common clean-profile stack in research use; GHRP-2 and GHRP-6 are less common pairings because of their cortisol/prolactin/appetite side effects. Our GHRH-plus-GHRP explainer walks through the pharmacology and typical timing.

Clinical Evidence

Mod GRF (1-29) as a distinct entity has essentially no dedicated human clinical trial program. The published pharmacology comes primarily from:

• ConjuChem's CJC-1295 development program. Early-phase trials in the mid-2000s characterized the pharmacodynamics of both the DAC and non-DAC forms, though these focused on the DAC version that went forward into development.
• Academic GHRH-analogue research. Tesamorelin, the GHRH analogue that did reach FDA approval (for HIV-associated lipodystrophy), provides the best adjacent evidence for what a stabilized GHRH fragment can do clinically. See tesamorelin for that profile.
• Community and compounding-pharmacy data. Clinical experience with Mod GRF in anti-aging practice is real but largely anecdotal rather than trial-derived.

Practical Considerations

Typical research-use dosing is 100-200 mcg subcutaneously, two to three times daily, dosed simultaneously with a GHRP on an empty stomach. Timing is coordinated with endogenous GH-release windows — before bed and on waking are the most common slots. Because both Mod GRF and a paired GHRP are short-acting, the stack produces discrete GH pulses rather than sustained elevation, which is generally considered preferable for maintaining pituitary responsiveness over longer cycles.

Safety and Regulatory Status

Reported side effects mirror other GHRH analogues: transient facial flushing shortly after injection, mild injection-site reactions, occasional headache, and — at higher sustained doses — water retention or joint discomfort. Because Mod GRF works through the physiologic GHRH receptor with preserved feedback, the risks associated with rhGH overdosing are substantially reduced at standard doses.

Mod GRF (1-29) is not FDA-approved for any indication. It is on the WADA prohibited list at all times (class S2). Supply is through research-chemical vendors and compounding pharmacies, with the variability in peptide purity and content that comes with that channel.